G01N 2333/535
Granulocyte csf
Official title: Granulocyte CSF; Granulocyte-macrophage CSF
G01N2333/535 (Granulocyte csf) appears on 31 US grants and 79 published applications in this corpus.
Search patents in G01N- Granted patents
- 31
- Published applications
- 79
- Assignees
- 64
- Inventors
- 199
- Latest grant
- 17 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 2 |
| 2009 | 0 | 1 |
| 2010 | 0 | 4 |
| 2011 | 1 | 1 |
| 2012 | 1 | 5 |
| 2013 | 2 | 5 |
| 2014 | 0 | 5 |
| 2015 | 1 | 4 |
| 2016 | 1 | 2 |
| 2017 | 2 | 6 |
| 2018 | 2 | 7 |
| 2019 | 2 | 6 |
| 2020 | 2 | 3 |
| 2021 | 3 | 3 |
| 2022 | 2 | 3 |
| 2023 | 1 | 6 |
| 2024 | 3 | 5 |
| 2025 | 3 | 3 |
| 2026 | 1 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of detecting and treating cerebral aneurysms17 Feb 2026US 12,553,904 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Diagnostic and treatment of chronic pathologies such as Lyme disease2 Dec 2025US 12,486,545 B2Centre National De La Recherche Scientifique
- System for detecting infection in synovial fluid12 Aug 2025US 12,385,909 B2CD Diagnostics, Inc.
- Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof6 May 2025US 12,291,567 B2Elixiron Immunotherapeutics (Hong Kong) Limited
- Gene expression markers and treatment of multiple sclerosis24 Sep 2024US 12,098,426 B2Genentech, Inc.
- Multi-Analyte Rapid Diagnostic Test for Sepsis Using Novel Biomarkers and Quantum Dot Technology1 Oct 2026US 2026/0298921 A1Trimar Domestic Inc.
- Humoral Immune Activators for the Treatment of Humoral Immunosuppressed Pathologies, Cancer and Infectious Disease and Humoral Immune Suppressors for the Treatment of Inflammatory Diseases3 Sep 2026US 2026/0256811 A1Navrogen, Inc.
- Viral infection modulation in vaccinated subjects treated with granulocyte-macrophage colony-stimulating factor (gm-csf)20 Aug 2026US 2026/0240950 A1Partner Therapeutics, Inc.
- Systemic biomarkers for the dynamic assessment of tumor burden and treatment efficacy in high grade gliomas2 Jul 2026US 2026/0188489 A1Mary Hitchcock Memorial Hospital, for itself and on behalf of Dartmouth-Hitchcock Clinic
- Methods of detecting and treating cerebral aneurysms19 Feb 2026US 2026/0049998 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
Most cited
By later US patents
- Monoclonal antibodies and method for the determination of human G-CSF38US 5,468,846 AKirin-Amgen, Inc. · 1995
- Methods of identifying biologically active receptor-binding peptides33US 5,837,460 AThe Trustees of the University of Pennsylvania · 1998
- Vagus nerve stimulation pre-screening test17US 11,173,307 B2SetPoint Medical Corporation · 2021
- Identification of M-CSF agonists and antagonists5US 6,025,146 AChiron Corporation · 2000
- Vagus nerve stimulation pre-screening test4US 11,890,471 B2SetPoint Medical Corporation · 2024